 Shares of Ocugen Inc. OCGN, -2.40 gained 4.7 in premarket trading on Friday after the company said the Food and Drug Administration lifted the clinical hold for the COVID-19 vaccine its developing with Bharat Biotech, a privately held biotech based in Hyderabad. The vaccine candidate is currently in a Phase 23 clinical trial, and Ocugen said it expects to start this immuno-bridging and broadening clinical trial as soon as possible. 